Detalhe da pesquisa
1.
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
Mov Disord
; 39(2): 350-359, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37886872
2.
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.
Mov Disord
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38698639
3.
Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.
Mov Disord
; 39(3): 606-613, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38389433
4.
Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.
Mov Disord
; 38(10): 1774-1785, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363815
5.
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
Ann Neurol
; 88(3): 574-587, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32542885
6.
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
Mov Disord
; 36(1): 59-63, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026697
7.
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
Mov Disord
; 36(11): 2687-2692, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496081
8.
The triple aim of clinical research.
Clin Trials
; 18(4): 511-513, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33878933
9.
Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.
Mov Disord
; 35(6): 1055-1061, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32251552
10.
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
Mov Disord
; 35(11): 1999-2008, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32798333
11.
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Mov Disord
; 35(5): 833-844, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32073681
12.
Sample enrichment for clinical trials to show delay of onset in huntington disease.
Mov Disord
; 34(2): 274-280, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30644132
13.
Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
Mov Disord
; 34(3): 425-429, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30653246
14.
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
Mov Disord
; 34(9): 1354-1364, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31361367
15.
Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
J Neurol Neurosurg Psychiatry
; 89(1): 78-88, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28986467
16.
Huntington's disease: Current and future therapeutic prospects.
Mov Disord
; 33(7): 1033-1041, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29737569
17.
Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.
Mov Disord
; 33(4): 520-527, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29573469
18.
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.
Mov Disord
; 33(5): 771-782, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29572948
19.
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
N Engl J Med
; 370(4): 311-21, 2014 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450890
20.
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
Mov Disord
; 32(3): 319-324, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28233927